- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled AR-501, Inhaled Placebo
- Drug
- Lead sponsor
- Aridis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,765
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Erythropoietic Protoporphyria (EPP)
- Interventions
- MT-7117 low dose, MT-7117 high dose, Placebo
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
- Conditions
- Precancerous Condition
- Interventions
- perillyl alcohol, placebo
- Drug · Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Acquired Antithrombin Deficiency
- Interventions
- Human plasma derived antithrombin, Placebo
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Acetazolamide, Placebo, Formal weight loss counselling program
- Drug · Behavioral
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
- Conditions
- Hereditary Angioedema
- Interventions
- Factor XIIa antagonist monoclonal antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
- Conditions
- COVID-19
- Interventions
- IBI314, Placebo
- Biological · Other
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 19
- States / cities
- Anaheim, California • Long Beach, California • San Diego, California + 12 more
- Conditions
- Alcoholism
- Interventions
- Ethanol, Placebo, Diphenhydramine, Caffeine
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetic Nephropathy, Endothelial Dysfunction
- Interventions
- flavonoids
- Dietary Supplement
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 12 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Amarillo, Texas
- Conditions
- Acute Pain, Wound Care, Posttraumatic Stress Disorder
- Interventions
- ketamine, Fentanyl
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Eye Disease
- Interventions
- OK-101, Placebo
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ, IVA, VX-440, Matched Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
- Conditions
- HIV Infections
- Interventions
- VH4011499 low dose Injection, VH4011499 high dose Injection, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Austin, Texas
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia
- Interventions
- Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Endometriosis
- Interventions
- Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Streptococcus Pneumoniae
- Interventions
- PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 84 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 37
- States / cities
- Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
- Conditions
- Dengue
- Interventions
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Acute Pain
- Interventions
- IV Acetaminophen, IV Control
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Orange, California • San Diego, California + 19 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Rotigotine, Placebo
- Drug · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more
- Conditions
- Cystic Fibrosis
- Interventions
- Cysteamine, Placebo Oral Capsule
- Drug
- Lead sponsor
- NovaBiotics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 179
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more
- Conditions
- HIV, Inflammation, Atherosclerosis
- Interventions
- Folic Acid, Placebo, Low Dose Methotrexate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thyroid Cancer, Differentiated Thyroid Carcinoma
- Interventions
- Lithium Carbonate, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland